Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

International Training for Doctoral Research on Advanced Gene and Cell Therapies

Project description

Training future leaders in cell and gene therapy

Gene therapy and gene editing are transforming medicine by offering treatments for rare, incurable genetic diseases. The field has seen rapid growth recently, creating the need for more scientists with specialised expertise in related research and real-world application. With the support of the Marie Skłodowska-Curie Actions programme, the RAREFIND project will train 22 doctoral candidates in advanced gene and cell therapies. The initiative is hosted by Fondazione Telethon in Italy and combines laboratory research with interdisciplinary training, industry placements and mentoring from leading scientists. The goal is to equip future experts with the necessary skills to translate genetic discoveries into therapies, ultimately improving outcomes for patients affected by rare diseases.

Objective

The RAREFIND project is an innovative doctoral training program designed to meet the growing need for specialized education in advanced gene and cell therapies. Coordinated by Fondazione Telethon (FTELE) with the School of Advanced Studies (IUSS) as implementing partner, RAREFIND offers a dynamic interdisciplinary and intersectoral training environment. The program encourages international mobility and promotes excellence in research across FTELE’s leading institutes, TIGEM and SR-TIGET, both recognized for their pioneering contributions to genetic research and therapy development. RAREFIND aims to train 22 doctoral candidates (DCs) through cutting-edge research projects on gene therapy, gene editing, and related fields. Participants, selected through a rigorous and competitive process, will receive comprehensive education combining scientific expertise with transferable skills. They will gain hands-on experience in leading laboratories, collaborate closely with non-academic entities, and benefit from secondments and specialized training. This approach ensures exposure to a broad range of perspectives, preparing DCs to advance the development of personalized therapies for rare genetic diseases.
A key pillar of the program is its emphasis on career development. RAREFIND offers tailored mentorship, targeted professional skills training, and opportunities to engage with leaders from academia, industry, and regulatory bodies. This holistic approach ensures that graduates are equipped not only for academic research careers but also for leadership roles in biotechnology, pharmaceutical companies, and other sectors in gene and cell therapies. By integrating translational research with real-world applications, RAREFIND accelerates the transformation of scientific discoveries into therapeutic solutions, strengthening Europe’s biomedical landscape.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-Cofund-D - HORIZON TMA MSCA Cofund Doctoral programme

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-COFUND-01

See all projects funded under this call

Coordinator

FONDAZIONE TELETHON ETS
Net EU contribution
€ 2 613 600,00
Address
VIA VARESE 16/B
00185 ROMA
Italy
Region
Centro (IT) Lazio Roma
Activity type
Research Organisations
Links
Total cost
No data